Compugen Company Profile (NASDAQ:CGEN)

About Compugen (NASDAQ:CGEN)

Compugen logoCompugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CGEN
  • CUSIP: N/A
  • Web: www.cgen.com
Capitalization:
  • Market Cap: $258.21 million
  • Outstanding Shares: 51,131,000
Average Prices:
  • 50 Day Moving Avg: $4.23
  • 200 Day Moving Avg: $4.87
  • 52 Week Range: $3.60 - $7.57
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.63
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $619,000.00
  • Price / Sales: 417.14
  • Book Value: $1.09 per share
  • Price / Book: 4.63
Profitability:
  • EBIDTA: ($30,920,000.00)
  • Net Margins: -261.77%
  • Return on Equity: -29.33%
  • Return on Assets: -26.61%
Debt:
  • Current Ratio: 14.91%
  • Quick Ratio: 14.91%
Misc:
  • Average Volume: 120,245 shs.
  • Beta: 1.18
  • Short Ratio: 12.75
 

Frequently Asked Questions for Compugen (NASDAQ:CGEN)

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) posted its earnings results on Tuesday, May, 9th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.01. Compugen had a negative return on equity of 29.33% and a negative net margin of 261.77%. View Compugen's Earnings History.

Where is Compugen's stock going? Where will Compugen's stock price be in 2017?

1 analysts have issued 12-month price targets for Compugen's shares. Their forecasts range from $14.00 to $14.00. On average, they anticipate Compugen's share price to reach $14.00 in the next twelve months. View Analyst Ratings for Compugen.

What are analysts saying about Compugen stock?

Here are some recent quotes from research analysts about Compugen stock:

  • 1. According to Zacks Investment Research, "Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen's expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. " (5/22/2017)
  • 2. FBR & Co analysts commented, "On February 15, Compugen hosted a conference call to discuss its 4Q16 and FY16 results, and announced that it is searching for a new chairperson for its board of directors to replace its current Chairman Martin Gerstel. We consider the decision benign as Mr. Gerstel’s decision to step down is motivated by his wish to fill the chair with someone who is seasoned in clinical development and commercialization as CGEN draws near to filing its first IND and advancing its own investigational therapy into the clinic. While Mr. Gerstel has successfully led CGEN from using its unique target prediction technologies through discovery of multiple drug targets, we think this decision is logical as CGEN transforms into a clinical-stage company. We look for the first IND filing expected in 4Q17 to be a significant inflection point in the company’s valuation." (2/16/2017)

Are investors shorting Compugen?

Compugen saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 1,881,937 shares, an increase of 1.7% from the April 13th total of 1,850,776 shares. Based on an average daily volume of 70,217 shares, the short-interest ratio is presently 26.8 days.

Who are some of Compugen's key competitors?

Who are Compugen's key executives?

Compugen's management team includes the folowing people:

  • Martin S. Gerstel, Chairman of the Board
  • Anat Cohen-Dayag Ph.D., President, Chief Executive Officer, Director
  • Ari Krashin, Chief Financial Officer
  • Zurit Levine Ph.D., Vice President - Research and Discovery
  • John Hunter, Vice President - Antibody Research & Development
  • Dov Hershberg, Director
  • Yair Aharonowitz Ph.D., Independent External Director
  • Ruth Arnon, Independent Director
  • Arie Ovadia, Independent External Director
  • Joshua Shemer M.D., Independent External Director

Who owns Compugen stock?

Compugen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Raging Capital Management LLC (8.29%), Morgan Stanley (1.59%), Renaissance Technologies LLC (1.14%), Rothschild Investment Corp IL (0.90%), Vanguard Group Inc. (0.45%) and Vident Investment Advisory LLC (0.29%). View Institutional Ownership Trends for Compugen.

Who sold Compugen stock? Who is selling Compugen stock?

Compugen's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Menta Capital LLC, Janney Montgomery Scott LLC, ProShare Advisors LLC and Rothschild Investment Corp IL. View Insider Buying and Selling for Compugen.

Who bought Compugen stock? Who is buying Compugen stock?

Compugen's stock was acquired by a variety of institutional investors in the last quarter, including Raging Capital Management LLC, Morgan Stanley, Renaissance Technologies LLC, Vident Investment Advisory LLC, Tower Research Capital LLC TRC, Goldman Sachs Group Inc., Benjamin F. Edwards & Company Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Compugen.

How do I buy Compugen stock?

Shares of Compugen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Compugen's stock price today?

One share of Compugen stock can currently be purchased for approximately $5.05.


MarketBeat Community Rating for Compugen (NASDAQ CGEN)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  111 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  165
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Compugen (NASDAQ:CGEN) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.00 (177.23% upside)

Analysts' Ratings History for Compugen (NASDAQ:CGEN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017FBR & CoSet Price TargetBuy$14.00HighView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$14.00 -> $11.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$14.00 -> $11.00N/AView Rating Details
2/11/2016Jefferies Group LLCReiterated RatingBuy$11.00 -> $9.00N/AView Rating Details
2/1/2016Oppenheimer Holdings Inc.Reiterated RatingBuyN/AView Rating Details
8/5/2015MLV & Co.Reiterated RatingBuy$14.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Compugen (NASDAQ:CGEN)
Earnings by Quarter for Compugen (NASDAQ:CGEN)
Earnings History by Quarter for Compugen (NASDAQ:CGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/20173/31/2017($0.18)($0.17)$0.06 millionViewListenView Earnings Details
2/15/2017Q416($0.18)($0.17)$0.13 million$0.05 millionViewListenView Earnings Details
11/7/2016Q316($0.14)($0.15)$0.41 million$0.07 millionViewN/AView Earnings Details
8/2/2016Q116($0.17)($0.13)$0.11 million$0.50 millionViewN/AView Earnings Details
5/10/2016Q1($0.16)($0.17)$0.12 million$0.09 millionViewListenView Earnings Details
2/9/2016Q415($0.11)($0.01)$3.33 million$8.30 millionViewN/AView Earnings Details
11/3/2015Q315($0.15)($0.13)$0.92 million$0.23 millionViewN/AView Earnings Details
8/4/2015Q215($0.14)($0.14)$1.58 million$0.22 millionViewN/AView Earnings Details
5/5/2015Q115($0.13)($0.12)$1.88 million$0.51 millionViewN/AView Earnings Details
2/10/2015Q414($0.08)($0.03)$3.70 million$6.60 millionViewN/AView Earnings Details
10/29/2014Q314($0.11)($0.11)$1.90 million$1.70 millionViewN/AView Earnings Details
8/6/2014Q214($0.10)($0.07)$1.85 million$2.00 millionViewN/AView Earnings Details
5/19/2014Q114($0.11)($0.04)$0.16 million$2.10 millionViewN/AView Earnings Details
2/11/2014Q413($0.09)$0.13 million$1.80 millionViewN/AView Earnings Details
10/29/2013Q313($0.12)$0.11 million$1.60 millionViewN/AView Earnings Details
11/5/2012Q312($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Compugen (NASDAQ:CGEN)
2017 EPS Consensus Estimate: ($0.65)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.18)($0.17)($0.18)
Q2 20172($0.17)($0.17)($0.17)
Q3 20172($0.18)($0.17)($0.18)
Q4 20172($0.17)($0.08)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Compugen (NASDAQ:CGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Compugen (NASDAQ:CGEN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Compugen (NASDAQ:CGEN)
Latest Headlines for Compugen (NASDAQ:CGEN)
Source:
DateHeadline
streetinsider.com logoCompugen (CGEN) Appoints Michal Preminger to Board of Directors - StreetInsider.com
www.streetinsider.com - May 25 at 5:43 PM
streetinsider.com logoCompugen (CGEN) Appoints Michal Preminger to Board of Directors - StreetInsider.com
www.streetinsider.com - May 25 at 5:43 PM
finance.yahoo.com logoCompugen Announces Appointment of Dr. Michal Preminger to Board of Directors
finance.yahoo.com - May 25 at 5:43 PM
finance.yahoo.com logoCompugen Announces Appointment of Dr. Michal Preminger to Board of Directors
finance.yahoo.com - May 25 at 5:43 PM
finance.yahoo.com logoCompugen to Present at Two Upcoming Investor Conferences in June
finance.yahoo.com - May 23 at 12:51 PM
americanbankingnews.com logoCompugen Ltd. (CGEN) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 22 at 6:26 PM
americanbankingnews.com logoCompugen Ltd. to Post FY2018 Earnings of $0.04 Per Share, FBR & Co Forecasts (CGEN)
www.americanbankingnews.com - May 22 at 9:16 AM
americanbankingnews.com logoCompugen Ltd. (CGEN) Given a $14.00 Price Target at FBR & Co
www.americanbankingnews.com - May 19 at 9:02 PM
americanbankingnews.com logo$210,000.00 in Sales Expected for Compugen Ltd. (CGEN) This Quarter
www.americanbankingnews.com - May 14 at 9:24 AM
americanbankingnews.com logoCompugen Ltd. (CGEN) Short Interest Up 1.7% in April
www.americanbankingnews.com - May 12 at 11:44 PM
americanbankingnews.com logoCompugen Ltd. (CGEN) Expected to Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - May 12 at 4:04 PM
americanbankingnews.com logoCompugen Ltd. (CGEN) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 4:56 PM
prnewswire.com logoCompugen Reports First Quarter 2017 Results - PR Newswire (press release)
www.prnewswire.com - May 10 at 8:25 AM
finance.yahoo.com logoCompugen reports 1Q loss
finance.yahoo.com - May 9 at 4:15 PM
finance.yahoo.com logoInvestor Network: Compugen Ltd. to Host Earnings Call
finance.yahoo.com - May 9 at 4:15 PM
finance.yahoo.com logoCompugen Reports First Quarter 2017 Results
finance.yahoo.com - May 9 at 8:20 AM
prnewswire.com logoCompugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO - PR Newswire (press release)
www.prnewswire.com - May 6 at 6:40 AM
finance.yahoo.com logoCompugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO
finance.yahoo.com - May 4 at 4:22 PM
finance.yahoo.com logoCompugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO
finance.yahoo.com - May 4 at 4:22 PM
americanbankingnews.com logoCompugen (CGEN) Receives Daily News Impact Rating of 0.40
www.americanbankingnews.com - May 4 at 1:10 AM
americanbankingnews.com logoCompugen (CGEN) Earning Somewhat Negative Press Coverage, Analysis Shows
www.americanbankingnews.com - April 28 at 12:42 PM
finance.yahoo.com logoCompugen First Quarter 2017 Conference Call Scheduled for Tuesday, May 9, 2017 at 10:00 AM ET
finance.yahoo.com - April 26 at 3:55 PM
finance.yahoo.com logoETFs with exposure to Compugen Ltd. : April 25, 2017
finance.yahoo.com - April 25 at 4:05 PM
americanbankingnews.com logoSomewhat Negative Press Coverage Extremely Likely to Affect Compugen (CGEN) Share Price
www.americanbankingnews.com - April 22 at 8:05 AM
americanbankingnews.com logoCompugen Ltd. (CGEN) Expected to Announce Earnings of -$0.18 Per Share
www.americanbankingnews.com - April 21 at 10:46 PM
americanbankingnews.com logoCompugen (CGEN) Given News Impact Score of 0.24
www.americanbankingnews.com - April 14 at 1:22 PM
finance.yahoo.com logoETFs with exposure to Compugen Ltd. : April 7, 2017
finance.yahoo.com - April 7 at 4:16 PM
reuters.com logoBRIEF-Compugen ltd selects of com902 as lead clinical antibody candidate for immuno-oncology program
www.reuters.com - March 28 at 9:03 PM
streetinsider.com logoForm 6-K COMPUGEN LTD For: Mar 28 - StreetInsider.com
www.streetinsider.com - March 28 at 12:46 PM
finance.yahoo.com logoCompugen Announces Lead Therapeutic Candidate COM902 for CGEN-15137/TIGIT Immuno-Oncology Program
finance.yahoo.com - March 28 at 12:46 PM
finance.yahoo.com logoCompugen to Present CGEN-15001 Autoimmune Product Candidate at Upcoming Conferences
finance.yahoo.com - March 22 at 3:16 PM
finance.yahoo.com logoCompugen Announces Addition of Prof. Miriam Merad to Its Scientific Advisory Board
finance.yahoo.com - March 8 at 4:59 PM
streetinsider.com logoCompugen (CGEN) Announces Presentations of Summary Results of COM701 at AACR - StreetInsider.com
www.streetinsider.com - March 3 at 4:15 PM
prnewswire.com logoCompugen Announces Presentations of COM701 Immuno-oncology Pipeline Product and Predictive Discovery ... - PR Newswire (press release)
www.prnewswire.com - March 2 at 7:12 AM
finance.yahoo.com logoCompugen Announces Presentations of COM701 Immuno-oncology Pipeline Product and Predictive Discovery Methodology for Novel Immune Checkpoints at AACR
finance.yahoo.com - March 2 at 7:12 AM
finance.yahoo.com logoCOMPUGEN LTD Financials
finance.yahoo.com - February 22 at 4:24 PM
us.rd.yahoo.com logoCompugen Reports Fourth Quarter and Calendar Year 2016 Results
us.rd.yahoo.com - February 16 at 9:30 AM
nasdaq.com logoFNY Managed Accounts LLC Buys Tesla, St Jude Medical, SPDR S&P 500, Sells LinkedIn, NXP ...
www.nasdaq.com - February 9 at 9:38 PM
finance.yahoo.com logoCompugen Fourth Quarter and Yearend 2016 Conference Call Scheduled for Wednesday, February 15, 2017 at 10:00 AM EST
finance.yahoo.com - January 30 at 5:00 PM
streetinsider.com logoCompugen (CGEN) Says CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity
www.streetinsider.com - January 4 at 5:18 PM
reuters.com logoBRIEF-Compugen says disclosed animal model results demonstrating restoration of immune tolerance by cgen-15001
www.reuters.com - January 4 at 5:18 PM
us.rd.yahoo.com logoCompugen's CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity
us.rd.yahoo.com - January 4 at 5:18 PM
nasdaq.com logoWhat Makes Compugen Ltd. (CGEN) a Strong Sell? - Nasdaq
www.nasdaq.com - December 22 at 4:24 PM
prnewswire.com logoCompugen Announces Key Highlights from R&D Day - PR Newswire - PR Newswire (press release)
www.prnewswire.com - December 8 at 5:03 PM
prnewswire.com logoCompugen Discloses its Cancer Immunotherapy Program Targeting ... - PR Newswire (press release)
www.prnewswire.com - December 8 at 5:03 PM
seekingalpha.com logoCompugen announces key highlights from R&D day - Seeking Alpha - Seeking Alpha
seekingalpha.com - December 8 at 5:03 PM
us.rd.yahoo.com logoCompugen Discloses its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint
us.rd.yahoo.com - December 7 at 4:54 PM
us.rd.yahoo.com logo7:26 am Compugen discusses data demonstrating that the CGEN-15029/PVRIG immune checkpoint represents a new inhibitory component of the known TIGIT axis at recent SITC Annual Meeting
us.rd.yahoo.com - December 7 at 4:54 PM
finance.yahoo.com logoCompugen Announces Key Highlights from R&D Day
finance.yahoo.com - December 7 at 4:54 PM
finance.yahoo.com logoCompugen Appoints Senior Vice President Corporate and Business Development
finance.yahoo.com - December 5 at 12:33 PM

Social

Chart

Compugen (CGEN) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff